[Contrast-unloading week in the complex therapy of patients with metabolic-alimentary obesity and its effect on changes in body weight and lipid metabolism indices]. 1979

V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova

The influences of the contrast-unloading week (CUW) on the changes in the anthropometric and lipid metabolism parameters was studied in 150 female patients with metabolic alimentary obesity of the II-III stages, aged from 20 to 40. On the basis of the analysis of the changes in lipid metabolism in relation to their initial level and the hyperlipoproteinemia type it is suggested that the developed CUW is mostly indicated in a combined therapy of patients with the IV type of hyperlipoproteinemia. In the II type it is recommended in combination with a dosaged physical loading. CUW can be used in out-patients, which is confirmed by the experience in the prophylactic examination of patients with metabolic alimentary obesity.

UI MeSH Term Description Entries
D006953 Hyperlipoproteinemia Type IV A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits. Hyperprebetalipoproteinemia,Hypertriglyceridemia, Familial,Carbohydrate Inducible Hyperlipemia,Carbohydrate-Inducible Hyperlipemia,Familial Hyperlipoproteinemia Type 4,Familial Type IV Hyperlipoproteinemia,Hyper prebeta lipoproteinemia,Hyperlipoproteinemia, Type IV,Carbohydrate Inducible Hyperlipemias,Carbohydrate-Inducible Hyperlipemias,Familial Hypertriglyceridemia,Hyperlipemia, Carbohydrate Inducible,Hyperlipemia, Carbohydrate-Inducible,Hyperlipemias, Carbohydrate Inducible,Hyperlipemias, Carbohydrate-Inducible,Hyperlipoproteinemias, Type IV,Inducible Hyperlipemia, Carbohydrate,Inducible Hyperlipemias, Carbohydrate,Type IV Hyperlipoproteinemia,Type IV Hyperlipoproteinemias,Type IV, Hyperlipoproteinemia
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D004038 Diet, Reducing A diet designed to cause an individual to lose weight. Weight Loss Diet,Weight Reduction Diet,Diet, Weight Loss,Diet, Weight Reduction,Diets, Reducing,Diets, Weight Loss,Diets, Weight Reduction,Reducing Diet,Reducing Diets,Weight Loss Diets,Weight Reduction Diets
D005081 Exercise Therapy A regimen or plan of physical activities designed and prescribed for specific therapeutic goals. Its purpose is to restore normal musculoskeletal function or to reduce pain caused by diseases or injuries. Rehabilitation Exercise,Remedial Exercise,Therapy, Exercise,Exercise Therapies,Exercise, Rehabilitation,Exercise, Remedial,Exercises, Rehabilitation,Exercises, Remedial,Rehabilitation Exercises,Remedial Exercises,Therapies, Exercise
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic

Related Publications

V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
January 1975, Voprosy meditsinskoi khimii,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
January 1986, Voprosy pitaniia,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
January 1977, Voprosy meditsinskoi khimii,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
November 1986, Wiener medizinische Wochenschrift (1946),
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
November 1965, Klinicheskaia meditsina,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
October 2012, Primary care diabetes,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
January 1984, Voprosy pitaniia,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
January 1997, Voprosy pitaniia,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
January 1965, Polskie Archiwum Medycyny Wewnetrznej,
V I Loĭko, and N N Baketova, and E A Lebedeva, and V N Kolmakov, and E S Skovorodnikova
June 1971, Vrachebnoe delo,
Copied contents to your clipboard!